New stroke drug LT3001 tested in small trial – could it be safer?
NCT ID NCT04091945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase IIa trial tested a single dose of LT3001, a new drug, in 24 people who had an acute ischemic stroke within the past 24 hours. The main goal was to see if the drug causes dangerous bleeding in the brain compared to a placebo. Researchers also looked for early signs that the drug might help improve outcomes. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LT3001
What this could lead to
If successful, this could point toward a new treatment option for acute ischemic stroke that may help restore blood flow with a lower risk of bleeding.
What could go wrong
This is an early Phase IIa trial with only 24 participants, so results may not apply broadly. The main safety concern is bleeding in the brain, and the drug may not prove effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- THUNDER Stroke Study: Penumbra System with Thund NCT05437055
- Stroke Alarm Efficacy Trial (NCT06315192)
- IMPROVE-II: FAST Model for Stroke Reperfusion (NCT06330051)
- Virtual Reality Rehab for Stroke Recovery - NCT07674329
- Endovascular Therapy for Basilar Artery Stroke (NCT07672795)
- Oropharyngeal Suction Tube for Stroke Pneumonia NCT07647666
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chattanooga Center for Neurologic Research
Chattanooga, Tennessee, 37403, United States
-
China Medical University Hospital
Taichung, Taiwan
-
JFK Neuroscience Institute, JFK Medical Center
Edison, New Jersey, 08837, United States
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
Linkou Chang Gung Memorial Hospital
New Taipei City, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Medical University - Shuang Ho Hospital
New Taipei City, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Ohio State University - Wexner Medical Center
Columbus, Ohio, 43210, United States
-
University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536, United States